Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Effect of Chinese Herbal Formula (KSY) on HCV Carrier With Abnormal Liver Function

This study has been completed.
Information provided by (Responsible Party):
Chung-Hua Hsu, Taipei City Hospital Identifier:
First received: October 15, 2012
Last updated: May 28, 2014
Last verified: May 2014
The aim of the study is to examine whether the Chinese herbal formula (KSY) is effective on HCV Carrier With Abnormal Liver Function.

Condition Intervention Phase
Liver Function
Drug: KSY
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: An Evaluation of the Extract of KUAN SIN YIN on Hepatitis C: a Randomized, Double-blinded and Placebo-controlled Clinical Trial.

Further study details as provided by Taipei City Hospital:

Primary Outcome Measures:
  • HCV RNA titer [ Time Frame: 6 weeks ]

Secondary Outcome Measures:
  • Serum GPT level [ Time Frame: 6 weeks ]

Other Outcome Measures:
  • WHOQOL-BREF [ Time Frame: 6 weeks ]

Enrollment: 57
Study Start Date: August 2012
Study Completion Date: March 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: KSY diluted
KSY diluted, 100mg decoction by mouth per day for 6 weeks
Experimental: KSY
KSY, 100mg decoction by mouth per day for 6 weeks
Drug: KSY
Chinese herbal formula

Detailed Description:
percentage of change on HCV RNA titer and liver function (GPT).

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 40 < GPT <200 HCV carrier Age: 18-65 yrs old

Exclusion Criteria:

  • Creatinine >2.0 mg/dL Total bilirubin > 2.0mg/dL Not suitable patients diagnosis by physician in charge.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01708733

Taipei City Hospital
Taipei, Taiwan, 886
Sponsors and Collaborators
Taipei City Hospital
  More Information

Responsible Party: Chung-Hua Hsu, chief medical officer, Taipei City Hospital Identifier: NCT01708733     History of Changes
Other Study ID Numbers: 101001-62-010
Study First Received: October 15, 2012
Last Updated: May 28, 2014

Keywords provided by Taipei City Hospital:
HCV carrier
Chinese herbal medicine
Liver function
HCV RNA titer processed this record on April 26, 2017